このエントリーをはてなブックマークに追加
ID 66682
FullText URL
Author
Zhou, Wenhao Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawashima, Shusuke Department of Dermatology, Chiba University Graduate School of Medicine
Ishino, Takamasa Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawase, Katsushige Chiba Cancer Center, Research Institute
Ueda, Youki Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamashita, Kazuo KOTAI Biotechnologies, Inc.
Watanabe, Tomofumi Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawazu, Masahito Chiba Cancer Center, Research Institute, Division of Cell Therapy
Dansako, Hiromichi Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Suzuki, Yutaka Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo
Nishikawa, Hiroyoshi Department of Immunology, Nagoya University Graduate School of Medicine
Inozume, Takashi Department of Dermatology, Chiba University Graduate School of Medicine
Nagasaki, Joji Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Togashi, Yosuke Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID researchmap
Abstract
Immune checkpoint inhibitors exert clinical efficacy against various types of cancer through reinvigoration of exhausted CD8+ T cells that attack cancer cells directly in the tumor microenvironment (TME). Using single-cell sequencing and mouse models, we show that CXCL13, highly expressed in tumor-infiltrating exhausted CD8+ T cells, induces CD4+ follicular helper T (TFH) cell infiltration, contributing to anti-tumor immunity. Furthermore, a part of the TFH cells in the TME exhibits cytotoxicity and directly attacks major histocompatibility complex-II-expressing tumors. TFH-like cytotoxic CD4+ T cells have high LAG-3/BLIMP1 and low TCF1 expression without self-renewal ability, whereas non-cytotoxic TFH cells express low LAG-3/BLIMP1 and high TCF1 with self-renewal ability, closely resembling the relationship between terminally differentiated and stem-like progenitor exhaustion in CD8+ T cells, respectively. Our findings provide deep insights into TFH-like CD4+ T cell exhaustion with helper progenitor and cytotoxic differentiated functions, mediating anti-tumor immunity orchestrally with CD8+ T cells.
Keywords
cancer immunology
follicular helper T cell
cytotoxic CD4+ T cell
CXCL13
T cell exhaustion
stem-like progenitor exhaustion
terminally differentiated exhaustion
PD-1
LAG-3
TCF1
Note
Immune checkpoint inhibitors exert clinical efficacy against various types of cancer through reinvigoration of exhausted CD8+ T cells that attack cancer cells directly in the tumor microenvironment (TME). Using single-cell sequencing and mouse models, we show that CXCL13, highly expressed in tumor-infiltrating exhausted CD8+ T cells, induces CD4+ follicular helper T (TFH) cell infiltration, contributing to anti-tumor immunity. Furthermore, a part of the TFH cells in the TME exhibits cytotoxicity and directly attacks major histocompatibility complex-II-expressing tumors. TFH-like cytotoxic CD4+ T cells have high LAG-3/BLIMP1 and low TCF1 expression without self-renewal ability, whereas non-cytotoxic TFH cells express low LAG-3/BLIMP1 and high TCF1 with self-renewal ability, closely resembling the relationship between terminally differentiated and stem-like progenitor exhaustion in CD8+ T cells, respectively. Our findings provide deep insights into TFH-like CD4+ T cell exhaustion with helper progenitor and cytotoxic differentiated functions, mediating anti-tumor immunity orchestrally with CD8+ T cells.
Published Date
2024-02-27
Publication Title
Cell Reports
Volume
volume43
Issue
issue2
Publisher
Elsevier BV
Start Page
113797
ISSN
2211-1247
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© 2024 The Author(s).
File Version
publisher
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1016/j.celrep.2024.113797
License
http://creativecommons.org/licenses/by/4.0/
Funder Name
Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Japan Science and Technology Agency
Naito Foundation
Astellas Foundation for Research on Metabolic Disorders
Wesco Foundation
Uehara Memorial Foundation
Senri Life Science Foundation
Relay for Life Japan Cancer Society Foundation
Japan Research Foundation for Clinical Pharmacology
Takeda Science Foundation
Kowa Life Science Foundation
Chugai Foundation for Innovative Drug Discovery Science
Yasuda Medical Foundation
SGH Foundation
KOTAI Biotechnologies, Inc.
助成番号
22K1945904
21H05051
20H03694
19K08744
22K20824
22K15472
23K14594
19cm0106502
21cm0106383
19ck0106521h0001
22ck0106775h0001
22gm1810002s0101
21-211033868